- Home
- PGR vs BMY Comparison
PGR vs BMY Comparison
Compare PGR & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PGR | BMY |
|---|---|---|
| Founded | 1937 | 1887 |
| Country | United States | United States |
| Employees | N/A | 32500 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.2B | 123.7B |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | PGR | BMY |
|---|---|---|
| Price | $204.89 | $57.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 16 |
| Target Price | ★ $240.85 | $61.81 |
| AVG Volume (30 Days) | 2.5M | ★ 10.0M |
| Earning Date | 04-15-2026 | 04-30-2026 |
| Dividend Yield | ★ 6.75% | 4.38% |
| EPS Growth | ★ 33.54 | N/A |
| EPS | ★ 19.23 | N/A |
| Revenue | ★ $87,671,000,000.00 | N/A |
| Revenue This Year | $3.35 | N/A |
| Revenue Next Year | $8.05 | N/A |
| P/E Ratio | ★ $10.68 | $17.26 |
| Revenue Growth | ★ 16.32 | N/A |
| 52 Week Low | $197.92 | $42.52 |
| 52 Week High | $289.88 | $62.89 |
Technical Indicators
Market Signals| Indicator | PGR | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 48.33 | 38.23 |
| Support Level | $198.77 | $53.88 |
| Resistance Level | $215.87 | $62.47 |
| Average True Range (ATR) | 4.07 | 1.19 |
| MACD | -0.21 | -0.53 |
| Stochastic Oscillator | 46.32 | 7.58 |
Price Performance
Historical ComparisonAbout PGR Progressive Corporation (The)
Progressive underwrites private and commercial auto insurance and specialty lines; it has almost 27 million personal auto policies in force and is one of the largest auto insurers in the United States. Progressive markets its policies through independent insurance agencies in the US and Canada and directly via the internet and telephone. Its premiums are split between the agent and the direct channel. The company also offers commercial auto policies and entered homeowners insurance through an acquisition in 2015.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.